- Home
- HOWL vs QNCX Comparison
HOWL vs QNCX Comparison
Compare HOWL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- QNCX
- Stock Information
- Founded
- HOWL 2017
- QNCX 2012
- Country
- HOWL United States
- QNCX United States
- Employees
- HOWL N/A
- QNCX N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOWL Health Care
- QNCX Health Care
- Exchange
- HOWL Nasdaq
- QNCX Nasdaq
- Market Cap
- HOWL 53.4M
- QNCX 47.7M
- IPO Year
- HOWL 2021
- QNCX 2019
- Fundamental
- Price
- HOWL $1.07
- QNCX $1.64
- Analyst Decision
- HOWL Strong Buy
- QNCX Strong Buy
- Analyst Count
- HOWL 3
- QNCX 5
- Target Price
- HOWL $8.33
- QNCX $8.00
- AVG Volume (30 Days)
- HOWL 612.4K
- QNCX 353.3K
- Earning Date
- HOWL 08-07-2025
- QNCX 08-12-2025
- Dividend Yield
- HOWL N/A
- QNCX N/A
- EPS Growth
- HOWL N/A
- QNCX N/A
- EPS
- HOWL N/A
- QNCX N/A
- Revenue
- HOWL $1,143,000.00
- QNCX N/A
- Revenue This Year
- HOWL N/A
- QNCX N/A
- Revenue Next Year
- HOWL N/A
- QNCX N/A
- P/E Ratio
- HOWL N/A
- QNCX N/A
- Revenue Growth
- HOWL N/A
- QNCX N/A
- 52 Week Low
- HOWL $0.60
- QNCX $0.51
- 52 Week High
- HOWL $4.18
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- HOWL 43.95
- QNCX 64.95
- Support Level
- HOWL $1.02
- QNCX $1.48
- Resistance Level
- HOWL $1.12
- QNCX $1.68
- Average True Range (ATR)
- HOWL 0.09
- QNCX 0.14
- MACD
- HOWL -0.03
- QNCX 0.02
- Stochastic Oscillator
- HOWL 16.67
- QNCX 85.71
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.